MOTS-c and Magnesium: No Direct Combination Study

Two Familiar Mechanisms Do Not Create a Combination Trial

Magnesium participates in hundreds of enzymatic reactions, including energy metabolism, glucose control, muscle function, and nerve function. MOTS-c is studied in cell and mouse metabolic pathways that include AMPK. That overlap makes the combination sound coherent, but it does not reveal absorption, exposure, net effect, or adverse-event frequency in people.

The established supplement side of the question also has real boundaries. NIH’s Office of Dietary Supplements states:

“High doses of magnesium from dietary supplements or medications can cause diarrhea, nausea, and abdominal cramping.”

The issuer is the National Institutes of Health Office of Dietary Supplements, which develops evidence-based nutrient fact sheets. This 16-word excerpt is about supplemental or medication magnesium, not foods, MOTS-c, or endorsement of a specific product (NIH ODS, Magnesium—Health Professional Fact Sheet).

The Combination-Evidence Matrix

The last column cannot be filled by combining facts from the first two.

What Current Magnesium Research Adds

A 2026 systematic review and meta-analysis included 15 randomized trials with 1,085 participants who had diabetes or prediabetes. Overall, oral magnesium did not produce a statistically significant change in insulin or HOMA-IR; baseline insulin resistance appeared to modify response in meta-regression (PMID 42426860; DOI 10.1186/s40795-026-01424-y).

That analysis corrects a simplistic claim that magnesium reliably “supports” MOTS-c through additive insulin sensitization. It studied magnesium versus placebo, not MOTS-c, and it does not prove that the combination is ineffective or harmful. It shows why a pathway claim should not replace controlled outcomes.

A 2024 randomized crossover trial in 14 people with insulin-treated type 2 diabetes and low serum magnesium found that supplementation raised serum magnesium but did not improve clamp-measured insulin sensitivity (PMID 37922013; PMCID PMC10709477). Its small, selected population does not answer the combination question either.

The MOTS-c Evidence Gap Controls the Answer

FDA’s July 2026 review found no clinical studies or human exposure data for administered MOTS-c by any route, no human pharmacokinetic study, and unresolved injectable-product concerns involving aggregation, impurities, and immunogenicity (FDA, Evaluation of MOTS-c-Related Bulk Drug Substances, sections II.C.2 and II.D.2, PDF pages 27–31).

NCT07505745 is recruiting adults with prediabetes and overweight or obesity, but no results are posted and the registry does not list a magnesium-combination arm (ClinicalTrials.gov NCT07505745). Without administered-human MOTS-c exposure, the page cannot declare that there is no pharmacokinetic conflict, that dose separation is unnecessary, or that most adults can use both safely.

The creatine combination audit applies the same two-stream reasoning to a different supplement.

Magnesium Decisions Still Need Their Own Context

“Magnesium” is not one exposure. Food, a labeled supplement, an antacid, and a laxative can deliver different amounts and salt forms. The Supplement Facts panel declares elemental magnesium, not the total compound weight. Kidney function, gastrointestinal disease, other sources, and interacting medicines can materially change risk (NIH ODS fact sheet).

NIH notes that the risk of magnesium toxicity increases with impaired renal function because the body’s ability to remove excess magnesium is reduced. The fact sheet also describes timing considerations for certain antibiotics and bisphosphonates and magnesium changes associated with diuretics and long-term proton-pump inhibitor use. Those are magnesium-specific issues, not evidence of a MOTS-c interaction.

What the Legacy Page Invented

The previous version answered “yes,” recommended magnesium forms and daily amounts, supplied target serum ranges, claimed additive insulin sensitization, set quarterly laboratory checkpoints, and cited an unpublished 84-person compounded-MOTS-c cohort. No inspectable source supported that cohort. FDA’s evidence review contradicts the premise that Phase I administered-human MOTS-c data already existed.

This revision does not replace those numbers with a different universal protocol. The clinically useful question is why magnesium is being considered—documented deficiency, diet, constipation, migraine, sleep, or another goal—and what evidence applies to that goal and product.

The young-adult evidence map explains the empty human treatment denominator. The rare-risk review distinguishes potential injectable-product risks from observed events.

Medical review of this revision is pending. NIH, FDA, investigators, authors, trial sponsors, journals, and institutions do not endorse MOTS-c, magnesium products, HealthRX.com, or this page.